6 Related NICE guidance
Published
-
Pemetrexed for the first-line treatment of non-small-cell lung cancer (2009) NICE technology appraisal guidance 181.
-
Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) (2009) NICE technology appraisal guidance175.
-
Erlotinib for the treatment of non-small-cell lung cancer (2008) NICE technology appraisal guidance 162.
-
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (2008) NICE technology appraisal guidance 148.
-
Pemetrexed for the treatment of non-small-cell lung cancer (2007) NICE technology appraisal guidance 124.
-
Lung cancer: the diagnosis and treatment of lung cancer (2005) NICE clinical guideline 24 [Replaced by NICE clinical guideline 121].
-
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (2010) NICE technology appraisal guidance 192.
-
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (2010) NICE technology appraisal guidance 227.
Under development
NICE is developing the following guidance(details available from the NICE website):
-
Cetuximab for the treatment of advanced non-small-cell lung cancer. NICE technology appraisal guidance(publication date to be confirmed).